Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:SDZNY)

68.52 +1.99 (+2.99%)
Streaming Delayed Price Updated: 3:51 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SDZNY

< Previous 1 2 Next >
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
From Sandoz
Via Business Wire
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
From Sandoz Group
Via GlobeNewswire
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
From Sandoz Group
Via GlobeNewswire
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
From Sandoz Group
Via GlobeNewswire
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
From Sandoz Group
Via GlobeNewswire
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic. 
Via Benzinga
Topics Intellectual Property
Life Sciences Investor Forum: Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
From Sandoz Group
Via GlobeNewswire
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
From Sandoz Group
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for June 11th-12th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
From Sandoz Group
Via GlobeNewswire
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
From Sandoz Group
Via GlobeNewswire
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
From Sandoz Group
Via GlobeNewswire
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market. 
Via Benzinga
Topics Intellectual Property Lawsuit
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
From Sandoz Group
Via GlobeNewswire
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
From Sandoz Group
Via GlobeNewswire
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
From Sandoz Group
Via GlobeNewswire
Sandoz reports strong FY 2024 results and Q4 2024 sales
From Sandoz Group
Via GlobeNewswire
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing... 
Via Benzinga
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
From Sandoz Group
Via GlobeNewswire
Francisco Ballester to retire; Peter Stenico appointed President Region International
From Sandoz Group
Via GlobeNewswire
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
From Sandoz Group
Via GlobeNewswire
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
From Sandoz Group
Via GlobeNewswire
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC. 
Via Benzinga
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
From Sandoz Group
Via GlobeNewswire
Sandoz reports third-quarter and nine-month 2024 sales
From Sandoz Group
Via GlobeNewswire
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
From Sandoz Group
Via GlobeNewswire
Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines
Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines 
Via News Direct
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
From Sandoz Group
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.